Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1998-11-30
pubmed:abstractText
A number of studies have suggested that an immune response to human leukocyte antigen (HLA) alloantigens may contribute to protection against HIV infection. In the present study, we examined the effect of alloantigen-stimulated cell lines obtained from peripheral blood mononuclear cells (PBMC) of HIV-uninfected (HIV-) individuals and the soluble factors produced by these cell lines on HIV-1 replication. Multiple in vitro restimulation with irradiated allogeneic PBMC from HIV- donors resulted in the expansion of CD8(+) T-cell lines that inhibited HIV-1 replication when cocultured with either autologous or heterologous in vitro-infected phytohemagglutinin (PHA) blasts. Supernatants from the alloantigen-stimulated cell lines also inhibited HIV replication in both PHA blasts and a chronically infected cell line. The alloantigen-stimulated cell lines and the factors they produced inhibited both T-cell-tropic (T) and macrophage-tropic (M) isolates of HIV-1. Blocking experiments using anti-chemokine antibodies suggested that this inhibition of HIV replication was not due to the beta-chemokines present in cocultures of cell lines with HIV-infected blasts. These results indicate that alloantigen-stimulation of PBMC from HIV- individuals activates CD8(+) T cells that produce soluble factor(s) that inhibit HIV replication of a wide spectrum of HIV-1 isolates through a chemokine-independent mechanism. This is a US government work. There are no restrictions on its use.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3346-54
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:9787172-Antibodies, Monoclonal, pubmed-meshheading:9787172-Biological Factors, pubmed-meshheading:9787172-CD8-Positive T-Lymphocytes, pubmed-meshheading:9787172-Cell Line, pubmed-meshheading:9787172-Chemokines, pubmed-meshheading:9787172-Culture Media, Conditioned, pubmed-meshheading:9787172-HIV-1, pubmed-meshheading:9787172-Histocompatibility, pubmed-meshheading:9787172-Humans, pubmed-meshheading:9787172-Isoantigens, pubmed-meshheading:9787172-Leukocytes, Mononuclear, pubmed-meshheading:9787172-Lymphocyte Activation, pubmed-meshheading:9787172-Lymphokines, pubmed-meshheading:9787172-Macrophages, pubmed-meshheading:9787172-Phytohemagglutinins, pubmed-meshheading:9787172-Receptors, HIV, pubmed-meshheading:9787172-T-Lymphocytes, pubmed-meshheading:9787172-Virus Replication
pubmed:year
1998
pubmed:articleTitle
Alloantigen-stimulated anti-HIV activity.
pubmed:affiliation
Experimental Immunology Branch and Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
pubmed:publicationType
Journal Article